Clinical application value of nipple-sparing mastectomy in breast cancer

doi:10.3760/cma.j.issn.1673-422X.2014.11.020

Abstract

Abstract: ObjectiveTo investigate the clinical efficacy, curative effects and cosmetic results of nipplesparing modified radical mastectomy (NSM) in the treatment of breast cancer. MethodsNinetysix patients who received initial therapy in Linyi Cancer Hospital from January 1, 2007 to January 1, 2010 were selected. Among them, 35 patients undergoing NSM were chosen as NSM group, 61 patients undergoing modified radical mastectomy (MRM) were chosen as MRM group. The postoperative complications, aesthetic assessment, local recurrence and distant metastasis of the two groups were compared. ResultsIn postoperative complications, the difference of the two groups had no statistical significance (χ2=3.140, P=0.061). NSM group was better than MRM group in aesthetic evaluation (χ2=82.786, P=0.000). Followup was obtained in all patients with range of 48 to 84 months and 63 months in average. Neither of them had local recurrence. Two patients(5.7%) in NSM group and three patients(4.9%) in MRM group developed distant metastasis. The incidents of distant metastasis had no statistically significant difference (χ2=0.029, P=0.866). ConclusionNSM can obtain the same therapeutic effect as MRM, and is easily accepted by patients before operation and has the better aesthetic assessment after operation. NSM is worth spreading widely.

Key words: Breast neoplasms, Mastectomy, modified radical

KONG Ling-Yu, SU Chuan-Fu. Clinical application value of nipple-sparing mastectomy in breast cancer[J]. Journal of International Oncology, 2014, 41(11): 866-869.

References

［1］张保宁, 邵志敏, 乔新民, 等. 中国乳腺癌保乳治疗的前瞻性多中心研究［J］. 中华肿瘤杂志, 2005, 27(11):680684. ［2］ Deutsch M, Land SR, Begovic M, et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B04 and B06［J］. Cancer, 2003, 98(7):13621368. ［3］ BlichertToft M, Nielsen M, Düring M, et al. Longterm results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20year followup of the Danish randomized DBCG82TM protocol［J］. Acta Oncol, 2008, 47(4):672681. ［4］ Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage ⅠⅡ breast cancer: 20 year followup of the EORTC 10801 phase 3 randomised trial［J］. Lancet Oncol, 2012, 13(4):412419. ［5］ Eriksen C, Frisell J,Wickman M,et al.Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study［J］. Breast Cancer Res Treat, 2011, 127(2):439446. ［6］左文述, 杨莉, 于志勇. 可手术乳腺癌局部外科治疗的临床实践［J］. 中华乳腺病杂志（电子版）, 2012, 6(1):18. ［7］ Isern AE, Manjer J, Malina J, et al. Risk of recurrence following delayed large flap reconstruction after mastectomy for breast cancer［J］. Br J Surg, 2011, 98(5):659666.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.